Photo by nci from unsplash
treat (ITT) is 71% and 57%, respectively (Figure 1). Conclusion: Ibrutinib dosed at 840 mg daily in combination with R‐ICE is well tolerated and enables HPC collection. Encouragingly, 89% of… Click to show full abstract
treat (ITT) is 71% and 57%, respectively (Figure 1). Conclusion: Ibrutinib dosed at 840 mg daily in combination with R‐ICE is well tolerated and enables HPC collection. Encouragingly, 89% of patients achieved a response; including 100% CMR in patients with non‐GCB phenotype disease. These results compare favorably to historic cohorts. Later phase studies for this treatment program are warranted, particularly for r/r non‐GCB patients.
Keywords:
combination;
study tirabrutinib;
results phase;
preliminary results;
tirabrutinib 4059;
phase study
Journal Title: Hematological Oncology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Hematological Oncology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!